Device Trial Radar · NCT04743635
CONtrolled Focal Fibrous Band Release Method Study
Last checked: Nov 20, 2026Latest source record: Jun 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
74
Actual
Start
Jan 7, 2021
Primary completion
Jun 14, 2021
Study completion Mar 4, 2022
Sponsor
- Lead sponsor
- Revelle Aesthetics, IncNot on our public-company list
- Sponsor type
- Industry
- First posted
- Feb 8, 2021
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- Female only, from 21 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Study to evaluate the safety and effectiveness of the Avéli medical device to reduce the appearance of cellulite.
Conditions
- Cellulite
Interventions
Avéli deviceDevice
Minimally invasive single procedure with the Avéli device for reduction in the appearance of cellulite in the thighs and buttocks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Mean Change From Baseline to 3 Months in Cellulite Severity Scale (CSS) Score for ParticipantsTime frame: 3 months
Locations
9 sites in 2 countries. Site status is shown where the registry gives one.
Clinical Site #3
Los Angeles, California
8 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.